XTX Topco Ltd Boosts Position in Guardant Health, Inc. (NASDAQ:GH)

XTX Topco Ltd boosted its position in Guardant Health, Inc. (NASDAQ:GH) by 76.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 31,457 shares of the company’s stock after purchasing an additional 13,624 shares during the period. XTX Topco Ltd’s holdings in Guardant Health were worth $961,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after acquiring an additional 29,686 shares during the period. Exome Asset Management LLC grew its holdings in Guardant Health by 13.7% during the third quarter. Exome Asset Management LLC now owns 89,800 shares of the company’s stock valued at $2,060,000 after purchasing an additional 10,800 shares during the period. Lord Abbett & CO. LLC bought a new stake in Guardant Health during the third quarter valued at about $15,624,000. Fiduciary Alliance LLC increased its position in Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock worth $363,000 after buying an additional 836 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC bought a new position in shares of Guardant Health in the fourth quarter worth about $252,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Price Performance

NASDAQ GH opened at $45.18 on Thursday. The company has a market cap of $5.58 billion, a price-to-earnings ratio of -12.69 and a beta of 1.45. The stock’s fifty day moving average price is $43.51 and its 200 day moving average price is $36.06. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Stephens reissued an “overweight” rating and issued a $55.00 target price on shares of Guardant Health in a report on Wednesday, March 26th. The Goldman Sachs Group increased their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Barclays dropped their target price on shares of Guardant Health from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Piper Sandler raised their price target on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Stifel Nicolaus upped their price objective on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of “Buy” and an average price target of $49.00.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.